COLL
Collegium Pharmaceutical, Inc. NASDAQ Listed May 7, 2015$39.33
After hrs
$35.70
-0.31%
Mkt Cap $1.3B
52w Low $26.81
52.2% of range
52w High $50.79
50d MA $35.29
200d MA $39.45
P/E (TTM)
17.3x
EV/EBITDA
5.4x
P/B
3.6x
Debt/Equity
3.1x
ROE
5.6%
P/FCF
4.5x
RSI (14)
—
ATR (14)
—
Beta
0.77
50d MA
$35.29
200d MA
$39.45
Avg Volume
503.7K
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
100 Technology Center Drive · Stoughton, MA 02072 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 36.51 | +2.7% | +7.7% | -3.9% | — | — | — | — |
| Feb 26, 2026 | AMC | 2.14 | 2.04 | -4.7% | 44.22 | -1.6% | -5.8% | -0.2% | -3.9% | -1.0% | -5.9% | — |
| Nov 6, 2025 | AMC | 1.86 | 2.25 | +21.0% | 40.66 | +0.6% | +4.0% | +2.9% | +3.0% | +5.6% | -2.0% | — |
| Aug 7, 2025 | AMC | 1.62 | 1.68 | +3.7% | 32.94 | +1.1% | +6.0% | +3.5% | +4.8% | -0.0% | -1.8% | — |
| May 8, 2025 | AMC | 1.43 | 1.49 | +4.2% | 27.27 | +8.8% | +5.9% | +2.3% | +0.8% | -2.4% | +0.9% | — |
| Feb 27, 2025 | AMC | 1.54 | 1.77 | +14.9% | 28.42 | +6.7% | +2.2% | -2.1% | -1.4% | +1.5% | +4.7% | — |
| Nov 7, 2024 | AMC | 1.59 | 1.61 | +1.3% | 34.71 | -4.9% | -7.3% | +0.1% | -2.4% | -3.9% | +0.3% | — |
| Aug 8, 2024 | AMC | 1.49 | 1.62 | +8.7% | 35.32 | -2.0% | +0.5% | +0.3% | +3.1% | -6.6% | +3.4% | — |
| May 9, 2024 | AMC | 1.47 | 1.45 | -1.4% | 37.86 | -12.8% | -16.8% | +2.1% | +3.5% | +2.1% | -0.9% | — |
| Feb 22, 2024 | AMC | 1.38 | 1.58 | +14.5% | 32.81 | +5.2% | +10.8% | +0.6% | +0.6% | -0.6% | +0.4% | — |
| Nov 7, 2023 | AMC | 1.22 | 1.34 | +9.8% | 21.68 | +9.8% | +6.6% | +5.6% | +0.3% | +2.9% | -0.3% | — |
| Aug 3, 2023 | AMC | 1.22 | 1.26 | +3.3% | 22.02 | +6.5% | +6.7% | +2.4% | +0.2% | -0.6% | +0.8% | — |
| May 4, 2023 | AMC | 1.33 | 1.32 | -0.8% | 22.20 | +1.3% | +3.2% | +2.2% | +0.5% | -1.9% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.30 | $36.31 | +0.0% | -2.4% | -2.0% | -4.3% | +0.1% | +0.5% |
| Mar 19 | Needham | Maintains | Buy → Buy | — | $34.80 | $35.64 | +2.4% | +4.3% | -2.4% | -2.0% | -4.3% | +0.1% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $45.75 | $41.75 | -8.7% | -3.3% | -5.8% | -0.2% | -3.9% | -1.0% |
| Jan 9 | Barclays | Maintains | Overweight → Overweight | — | $48.78 | $48.77 | -0.0% | -6.6% | +5.7% | -1.8% | -1.5% | +0.7% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.78 | $48.77 | -0.0% | -6.6% | +5.7% | -1.8% | -1.5% | +0.7% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $47.26 | $47.73 | +1.0% | +3.2% | -6.6% | +5.7% | -1.8% | -1.5% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $40.66 | $40.91 | +0.6% | +4.0% | +2.9% | +3.0% | +5.6% | -2.0% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.66 | $40.91 | +0.6% | +4.0% | +2.9% | +3.0% | +5.6% | -2.0% |
| Oct 28 | Needham | Maintains | Buy → Buy | — | $34.82 | $34.63 | -0.5% | +1.7% | -1.7% | +2.4% | +1.0% | +0.3% |
| May 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.27 | $29.66 | +8.8% | +5.9% | +2.3% | +0.8% | -2.4% | +0.9% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $25.41 | $24.79 | -2.4% | +3.8% | -6.4% | +6.6% | +1.6% | +1.5% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.05 | $30.43 | +1.3% | +1.7% | -1.3% | -0.6% | -1.3% | +0.5% |
| Feb 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $31.20 | $30.81 | -1.2% | -0.9% | -0.7% | +0.8% | -0.4% | -1.0% |
| Jan 10 | Needham | Upgrade | Hold → Buy | — | $33.34 | $33.92 | +1.7% | -1.3% | +2.7% | -1.8% | -0.7% | +1.5% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.34 | $33.92 | +1.7% | -1.3% | +2.7% | -1.8% | -0.7% | +1.5% |
| Oct 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $36.64 | $36.80 | +0.4% | +2.9% | +0.7% | +1.4% | +2.1% | -1.0% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.24 | $38.52 | +0.7% | -1.6% | -1.1% | -1.3% | -1.7% | +0.4% |
| Aug 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $35.32 | $34.61 | -2.0% | +0.5% | +0.3% | +3.1% | -6.6% | +3.4% |
| Aug 9 | Truist | Maintains | Buy → Buy | — | $35.32 | $34.61 | -2.0% | +0.5% | +0.3% | +3.1% | -6.6% | +3.4% |
| Jul 30 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $34.89 | $36.51 | +4.6% | +10.6% | -0.1% | +0.1% | -5.8% | -5.1% |
| Jun 7 | Jefferies | Upgrade | Hold → Buy | — | $31.36 | $32.57 | +3.9% | +5.8% | +0.4% | -2.2% | -2.1% | +0.2% |
| May 10 | Piper Sandler | Downgrade | Overweight → Neutral | — | $37.86 | $33.01 | -12.8% | -16.8% | +2.1% | +3.5% | +2.1% | -0.9% |
| May 10 | Needham | Downgrade | Buy → Hold | — | $37.86 | $33.01 | -12.8% | -16.8% | +2.1% | +3.5% | +2.1% | -0.9% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $37.99 | $37.97 | -0.1% | -4.2% | -1.9% | -1.6% | +0.7% | +0.1% |
| Feb 26 | Truist | Maintains | Buy → Buy | — | $36.35 | $36.36 | +0.0% | +0.6% | +0.6% | -0.6% | +0.4% | +1.1% |
| Feb 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.81 | $34.50 | +5.2% | +10.8% | +0.6% | +0.6% | -0.6% | +0.4% |
| Feb 2 | Needham | Maintains | Buy → Buy | — | $33.47 | $33.44 | -0.1% | -1.9% | +0.8% | +0.5% | -0.1% | +0.4% |
| Jan 4 | Truist | Maintains | Buy → Buy | — | $33.86 | $33.21 | -1.9% | -4.5% | -0.1% | -1.7% | +1.7% | +1.1% |
| Jan 4 | Jefferies | Downgrade | Buy → Hold | — | $33.86 | $33.21 | -1.9% | -4.5% | -0.1% | -1.7% | +1.7% | +1.1% |
| Jan 4 | Needham | Maintains | Buy → Buy | — | $33.86 | $33.21 | -1.9% | -4.5% | -0.1% | -1.7% | +1.7% | +1.1% |
| Aug 25 | Needham | Maintains | Buy → Buy | — | $23.51 | $23.84 | +1.4% | +1.5% | -1.6% | +1.4% | -1.0% | -0.7% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $22.02 | $23.46 | +6.5% | +6.7% | +2.4% | +0.2% | -0.6% | +0.8% |
| May 30 | Needham | Maintains | Buy → Buy | — | $22.53 | $22.58 | +0.2% | -3.2% | +1.2% | +1.3% | -3.2% | -2.6% |
| May 5 | Needham | Maintains | Buy → Buy | — | $22.20 | $22.49 | +1.3% | +3.2% | +2.2% | +0.5% | -1.9% | +0.2% |
| Apr 19 | Needham | Maintains | Buy → Buy | — | $23.14 | $23.13 | -0.0% | -1.1% | -0.2% | +1.0% | +1.4% | -2.6% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $26.60 | $27.60 | +3.8% | +0.9% | -0.2% | -1.0% | +1.0% | +1.6% |
| Feb 8 | Needham | Maintains | Buy → Buy | — | $28.12 | $27.44 | -2.4% | -4.6% | -0.4% | +0.1% | +0.7% | -0.4% |
| Jan 5 | Needham | Maintains | Buy → Buy | — | $26.98 | $27.10 | +0.4% | +3.9% | +2.2% | -2.6% | +1.9% | -3.8% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $18.03 | $19.19 | +6.4% | +4.5% | +6.1% | -1.3% | -2.5% | +0.2% |
| Aug 8 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $20.10 | $19.41 | -3.4% | -3.0% | -0.8% | +2.3% | -3.0% | -2.1% |
| Apr 6 | Needham | Maintains | Buy → Buy | — | $20.08 | $20.00 | -0.4% | +4.0% | -1.1% | -0.6% | -4.1% | -2.1% |
| Feb 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.75 | $22.75 | +4.6% | +1.9% | +1.5% | -4.9% | -9.5% | +0.6% |
| Feb 15 | Needham | Maintains | Buy → Buy | — | $19.90 | $20.71 | +4.1% | +9.6% | +2.1% | -1.3% | -1.1% | +1.9% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.90 | $20.71 | +4.1% | +9.6% | +2.1% | -1.3% | -1.1% | +1.9% |
| Nov 15 | Needham | Maintains | Buy → Buy | — | $19.48 | $20.50 | +5.2% | +2.7% | -0.7% | -1.5% | -2.6% | -1.0% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $19.35 | $18.99 | -1.9% | -1.5% | +6.7% | -0.0% | -0.6% | -0.4% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.84 | $20.81 | -16.2% | -17.3% | -3.1% | -4.4% | -2.0% | -2.3% |
| Aug 6 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $24.84 | $20.81 | -16.2% | -17.3% | -3.1% | -4.4% | -2.0% | -2.3% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $24.84 | $20.81 | -16.2% | -17.3% | -3.1% | -4.4% | -2.0% | -2.3% |
| Jan 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.69 | $22.45 | +3.5% | -2.4% | +1.8% | +1.2% | +2.1% | +7.9% |
No insider trades available.
8-K · 2.02
!! High
Collegium Pharmaceutical, Inc. -- 8-K 2.02: Earnings Results
Collegium Pharmaceutical reported earnings results in an 8-K filing, with the full press release available as an exhibit for investor review of the company's operational and financial performance.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of Dr. Fallon from the board removes a director whose contributions were significant, potentially signaling governance changes or internal disagreements that investors should monitor for strategic direction shifts.
Apr 7
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Collplant signed a $24M agreement with Corium, likely for technology licensing or partnership, potentially unlocking new revenue streams and validating its regenerative medicine platform's commercial value.
Mar 19
8-K · 7.01
! Medium
Collegium Pharmaceutical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Collegium Pharmaceutical furnished an investor presentation under Regulation FD Disclosure, suggesting the company is providing material non-public information to investors that must now be disclosed publicly.
Feb 26
Data updated apr 25, 2026 2:36am
· Source: massive.com